358 related articles for article (PubMed ID: 32206497)
1. Recent strategies towards the surface modification of liposomes: an innovative approach for different clinical applications.
Khan AA; Allemailem KS; Almatroodi SA; Almatroudi A; Rahmani AH
3 Biotech; 2020 Apr; 10(4):163. PubMed ID: 32206497
[TBL] [Abstract][Full Text] [Related]
2. Future directions of liposome- and immunoliposome-based cancer therapeutics.
Park JW; Benz CC; Martin FJ
Semin Oncol; 2004 Dec; 31(6 Suppl 13):196-205. PubMed ID: 15717745
[TBL] [Abstract][Full Text] [Related]
3. From conventional to stealth liposomes: a new frontier in cancer chemotherapy.
Cattel L; Ceruti M; Dosio F
Tumori; 2003; 89(3):237-49. PubMed ID: 12908776
[TBL] [Abstract][Full Text] [Related]
4. Liposomal doxorubicin as targeted delivery platform: Current trends in surface functionalization.
Makwana V; Karanjia J; Haselhorst T; Anoopkumar-Dukie S; Rudrawar S
Int J Pharm; 2021 Jan; 593():120117. PubMed ID: 33259901
[TBL] [Abstract][Full Text] [Related]
5. Stealth liposomes: review of the basic science, rationale, and clinical applications, existing and potential.
Immordino ML; Dosio F; Cattel L
Int J Nanomedicine; 2006; 1(3):297-315. PubMed ID: 17717971
[TBL] [Abstract][Full Text] [Related]
6. Liposome: classification, preparation, and applications.
Akbarzadeh A; Rezaei-Sadabady R; Davaran S; Joo SW; Zarghami N; Hanifehpour Y; Samiei M; Kouhi M; Nejati-Koshki K
Nanoscale Res Lett; 2013 Feb; 8(1):102. PubMed ID: 23432972
[TBL] [Abstract][Full Text] [Related]
7. Long circulating liposomes: challenges and opportunities.
Deodhar S; Dash AK
Ther Deliv; 2018 Nov; 9(12):857-872. PubMed ID: 30444455
[TBL] [Abstract][Full Text] [Related]
8. Approaches to Address PK-PD Challenges of Conventional Liposome Formulation with Special Reference to Cancer, Alzheimer's, Diabetes, and Glaucoma: An Update on Modified Liposomal Drug Delivery System.
Kesharwani P; Kumari K; Gururani R; Jain S; Sharma S
Curr Drug Metab; 2022; 23(9):678-692. PubMed ID: 35692131
[TBL] [Abstract][Full Text] [Related]
9. Liposomes as carriers of hydrophilic small molecule drugs: strategies to enhance encapsulation and delivery.
Eloy JO; Claro de Souza M; Petrilli R; Barcellos JP; Lee RJ; Marchetti JM
Colloids Surf B Biointerfaces; 2014 Nov; 123():345-63. PubMed ID: 25280609
[TBL] [Abstract][Full Text] [Related]
10. Targeted liposomal drug delivery: a nanoscience and biophysical perspective.
Liu Y; Castro Bravo KM; Liu J
Nanoscale Horiz; 2021 Feb; 6(2):78-94. PubMed ID: 33400747
[TBL] [Abstract][Full Text] [Related]
11. Liposomal drug formulations. Rationale for development and what we can expect for the future.
Allen TM
Drugs; 1998 Nov; 56(5):747-56. PubMed ID: 9829150
[TBL] [Abstract][Full Text] [Related]
12. Factors affecting microencapsulation of drugs in liposomes.
Kulkarni SB; Betageri GV; Singh M
J Microencapsul; 1995; 12(3):229-46. PubMed ID: 7650588
[TBL] [Abstract][Full Text] [Related]
13. Liposomal drug delivery systems: an update review.
Samad A; Sultana Y; Aqil M
Curr Drug Deliv; 2007 Oct; 4(4):297-305. PubMed ID: 17979650
[TBL] [Abstract][Full Text] [Related]
14. Peritoneal retention of liposomes: Effects of lipid composition, PEG coating and liposome charge.
Dadashzadeh S; Mirahmadi N; Babaei MH; Vali AM
J Control Release; 2010 Dec; 148(2):177-86. PubMed ID: 20800629
[TBL] [Abstract][Full Text] [Related]
15. Investigation of parameters influencing incorporation, retention and cellular cytotoxicity in liposomal formulations of poorly soluble camptothecin.
Whitaker RD; Ingebrigtsen SG; Naderkhani E; Skar ML; Flaten GE
J Liposome Res; 2013 Dec; 23(4):298-310. PubMed ID: 23763495
[TBL] [Abstract][Full Text] [Related]
16. Mechanism and kinetics of the loss of poorly soluble drugs from liposomal carriers studied by a novel flow field-flow fractionation-based drug release-/transfer-assay.
Hinna AH; Hupfeld S; Kuntsche J; Bauer-Brandl A; Brandl M
J Control Release; 2016 Jun; 232():228-37. PubMed ID: 27112112
[TBL] [Abstract][Full Text] [Related]
17. Pros and cons of the liposome platform in cancer drug targeting.
Gabizon AA; Shmeeda H; Zalipsky S
J Liposome Res; 2006; 16(3):175-83. PubMed ID: 16952872
[TBL] [Abstract][Full Text] [Related]
18. Pharmacokinetics of temoporfin-loaded liposome formulations: correlation of liposome and temoporfin blood concentration.
Decker C; Schubert H; May S; Fahr A
J Control Release; 2013 Mar; 166(3):277-85. PubMed ID: 23313962
[TBL] [Abstract][Full Text] [Related]
19. Liposomes as biocompatible and smart delivery systems - the current state.
Dymek M; Sikora E
Adv Colloid Interface Sci; 2022 Nov; 309():102757. PubMed ID: 36152374
[TBL] [Abstract][Full Text] [Related]
20. Towards clinical translation of ligand-functionalized liposomes in targeted cancer therapy: Challenges and opportunities.
Belfiore L; Saunders DN; Ranson M; Thurecht KJ; Storm G; Vine KL
J Control Release; 2018 May; 277():1-13. PubMed ID: 29501721
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
